Cladribine: Ortho Biotech Inc

Current Opinion in Investigational Drugs

Volumn 2, Issue 12, 2001, Pages 1751-1756

  Tortorella, Carla ^a   Rovaris, Marco ^a   Filippi, Massimo ^a  

^a Sci Inst Univ Osp San Raffaela   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE INHIBITOR; ANTIMETABOLITE; AZATHIOPRINE; BETA INTERFERON; CARBAMAZEPINE; CHLORAMBUCIL; CLADRIBINE; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; CYTOTOXIC AGENT; FLUDARABINE; GLATIRAMER; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; MITOXANTRONE; PENTOSTATIN; PHENYTOIN; PLACEBO; PURINE DERIVATIVE;

BONE MARROW SUPPRESSION; CARDIOTOXICITY; CELL LEVEL; CLINICAL SKIN REACTION; CLINICAL TRIAL; DOSE RESPONSE; DRUG ACTIVITY; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG ISOLATION; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; HEMATOLOGIC DISEASE; HUMAN; INFECTION; LEUKEMIA; MULTIPLE SCLEROSIS; MUSCLE HYPERTONIA; MUSCLE WEAKNESS; NAUSEA; NONHUMAN; PURPURA; REVIEW; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ADENOSINE DEAMINASE; ANIMALS; ANTINEOPLASTIC AGENTS; ARTHRITIS, RHEUMATOID; CLADRIBINE; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; ENZYME INHIBITORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA; MULTIPLE SCLEROSIS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0035686348     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Cladribine (2-chlorodeoxyadenosine)
2. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes
3. Antileukemic and immunosuppressive activity of 2-chloro-2′-deoxyadenosine
4. On the pharmacokinetics of 2-chloro-2′-deoxyadenosine in humans
5. Inhibitory effect of 2-chlorodeoxyadenosine on granulocytic, erythroid, and T-lymphocytic colony growth
6. On the bioavailability of oral and subcutaneous 2-chloro-2′-deoxyadenosine in humans: Alternative routes of administration
7. Johnson & Johnson
8. 2-Chrolodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia
9. Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia
10. Investigational agents for rheumatoid arthritis
11. US FDA Cladribine approved for hairy cell leukemia
12. Effect of repeated treatments with cladribine (2-chlorodeoxyadenosine) on blood counts in multiple sclerosis patients
13. Cladribine (2-chloro-2′-deoxyadenosine): New perspectives in clinical immunosuppression
14. Cladribine in treatment of chronic progressive multiple sclerosis
15. Marrow suppression produced by repeated doses of cladribine
16. In brief
17. In brief
18. ClinCon monitoring of Lotrisine and Floxin Otic studies inadequate, FDA says
19. Johnson & Johnson - 1997 mid-year report
20. IVAX to develop new drug for multiple sclerosis IVAX licenses cladribine, in advanced, clinical development, from The Scripps Research Institute
21. US Specialty pharmaceuticals: Monthly Dose - May
22. Whole brain volume changes in patients with progressive MS treated with cladribine
23. Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group
24. The effect of cladribine on T(1) 'black hole' changes in progressive MS
25. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis
26. Safety and tolerability of subcutaneous cladribine therapy in progressive multiple sclerosis
27. Administration of monthly pulses of cyclophosfamide in multiple sclerosis patients
28. Preferential reductions in lymphocyte subpopulations induced by monthly pulses of chlorambucil: Studies in patients with chronic progressive multiple sclerosis
29. The clinical pharmacokinetics of cladribine
30. Infectious and immunosuppressive complications of purine analog therapy
31. Rating neurological impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS)
32. A neurologic rating scale (NRS) for use in multiple sclerosis
33. Progressive cerebral atrophy in multiple sclerosis: A serial MRI study
34. Histopathological correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis
35. A comparison of the pathology of primary and secondary progressive multiple sclerosis
36. European Study Group on interferon β-1b in secondary progressive multiple sclerosis. Placebo-controlled multicentre randomized trial of interferon β-1b in treatment of secondary progressive multiple sclerosis
37. Effect of interferon beta 1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: Results of a European multicenter, randomized, double blind, placebo-controlled study
38. Multiple sclerosis: Immunotherapy